Affordable access to Covid-19 drugs: Are voluntary patent licences here to stay?

Remdesivir is presently considered the most promising candidate for the treatment of COVID-19, and is the subject matter of three Indian patents granted in 2016, 2019 and early 2020 respectively. Through the licenses, the licensee companies will be provided transfer of technology and would be able to set their own prices for the drug.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news